Background: Pregnancy in renal transplant recipient is a high risk pregnancy, associated with increased risk of graft rejection and other complications. Many pregnancies have been reported, still there is limited data on optimal counseling and clinical management of these patients. Objectives: To study maternal and fetal outcomes in renal transplant recipients. Material and methods: Study design: This is a retrospective observational study conducted at tertiary health center in Ahmedabad, from 2004 to 2014.
Sample size: There were 3016 renal transplant recipients out of which 2507 were males and 509 were females. Among 509 females, 211 recipients were in reproductive age group (20-40 years) who were included in the study. Out of 211 recipients, 113 (53.5%) had complete family, 46 (21.8%) did not tried for pregnancy, 33 (15.63%) were lost to follow up, 16 (7.58%) patients conceived and 3 (1.41%) were infertile. Method: Maternal and fetal outcomes were studied and patients were followed up till 2 years of postpartum.
Exclusion criteria: Unmarried, divorcee and widow patients were excluded. Results: There were 16 patients who had conceived, out of which 8 patients had abortions, 6 patients had full term deliveries and 2 patients had preterm delivery. Two patients developed newly diagnosed gestational hypertension from 20 weeks of gestation. One patient had graft rejection 2 months post abortion and one had cholestasis of pregnancy from 7 months of gestation. On follow up, one patient expired 1 year after abortion due to tuberculosis meningitis and one patient (10 months post abortion) is on intermittent hemodialysis since 3 months, after 1.5 years of renal transplant. Conclusion: These patients are at risks for developing many complications during pregnancy, out of which graft rejection is most grievous one. However, with proper peritransplant and periconceptional counseling regarding optimal time for pregnancy, these patients can have good pregnancy outcome.
ß 2016
were lost to follow up, 16 (7.58%) patients conceived and 3 (1.41%) were infertile. Method: Maternal and fetal outcomes were studied in terms of deliveries, abortion, fetal maturity and birth weight. During antenatal period these patients were followed monthly till 20 weeks, thereafter every fortnight till 28 weeks and weekly till term. Routine antenatal investigations like complete blood counts, random blood sugar, HIV and HbsAg were done. At each antenatal visit, patient's serum creatinine and urinary protein were done. All recipients underwent graft Doppler at 20 weeks of pregnancy to detect graft dysfunction. Fetal growth was closely monitored at each antenatal visit. Second trimester anomaly scan was done in every patient around 20-22 weeks of gestation. These patients were followed up in OPD with serum creatinine and urinary protein at 6 weeks and 3 months postpartum. Thereafter, they were followed annually for 2 year in gynecology department. Babies were followed up in pediatric OPD at interval of 6 months till 2 years of age, to detect any delay in developmental milestones.
Exclusion criteria: Unmarried, divorcee and widow patients were excluded.
Results
There were 16 patients who conceived, out of which 8 patients had abortions, 6 patients had full term deliveries and 2 patients had preterm delivery. The mean age of patients was 32.13 AE 4.53 years. The most common cause of renal transplant was crescentric glomerulonephritis (69%) followed by other causes (Fig. 1 ).
There were five patients who had past history of gestational hypertension and 4 patients who had past history of preeclampsia, which might had led to acute renal (in 2 patients) and chronic renal failure (in 7 patients) necessitating renal transplant for survival. The reason for these patients landing up for renal transplant might be inappropriate control of blood pressure and poor compliance in taking antihypertensive drugs in postpartum period.
The mean transplant pregnancy interval was 3.53 AE 2.17 years. Pregnancy outcome with respect to transplant pregnancy interval was studied (Table 1 ). It was found that patients with transplant pregnancy interval >2 years had good outcome, where out of 9 patients, 6 patients had delivered successfully with healthy babies, except one who had preterm delivery at 28 weeks.
The effect of serum creatinine pre-pregnancy and during antenatal period on pregnancy outcome was studied ( Table 2 ). The mean pre pregnancy serum creatinine level was 1.08 AE 0.25 mg/dl. The number of deliveries were more in patients with pre pregnancy serum creatinine <1.2 mg/dl whereas number of abortions were more in patients with serum creatinine >1.2 mg/dl. Patients with s.creatinine <1 mg/dl during antenatal period, one had preterm delivery at 34 weeks and 4 had pregnancy till term, whereas in patients with s.creatinine >1 mg/dl, out of 3 patients, one had preterm delivery at 28 weeks and 2 patients had term delivery.
All routine antenatal investigations like complete blood counts, blood urea nitrogen, urine routine examination were within normal limits, apart from 2 patients whose hemoglobin were 8gm/ dl. No gross anomaly was detected in fetus during antenatal scan. Graft Doppler was also normal in all antenatal patients.
Among antenatal complications, one patient had cholestasis of pregnancy from 7 months of gestation, which was managed conservatively. Nine patients were chronic hypertensive, out of which, six patients had missed abortion, 2 patients had term delivery who remained mild hypertensive throughout pregnancy and one developed preeclampsia superimposed on chronic hypertension around 34 weeks of gestation. Two patients developed newly diagnosed gestational hypertension from 20 weeks of gestation, out of which 1 patient developed preeclampsia at 32 weeks. Both preeclamptic patients were delivered around 36 weeks by cesarean section along with steroid coverage for fetus and delivered healthy babies.
Effect of various immunosuppressive agents on pregnancy outcome was also studied ( Table 3 ). Out of 8 pregnant patients, 2 had preterm deliveries. One patient delivered around 28 weeks and one patient at 34 weeks of gestation. Both preterm deliveries were due to PROM. All of them had cesarean delivery except one who had preterm vaginal delivery at 28 weeks.
The mean weight of babies was 2.19 AE 0.61 kg and mean maturity was 35.13 AE 2.80 weeks. Out of 8 babies, one expired due to cardiac anomaly (VSD) which was missed during antenatal period, one baby was in neonatal intensive care for 30 days because of prematurity and low bright weight (1 kg at 28 weeks), rest 6 babies were normal.
During postpartum follow up, one patient had acute graft rejection 2 months post abortion which was managed conservatively. However, one patient expired following 1 year after abortion due to tuberculosis meningitis and one patient is on intermittent hemodialysis since 3 months after 10 months of abortion (post 1.5 years of renal transplant).
Data analysis
All collected data were entered into the SPSS V20 and analysis has been conducted. Non continuous data are countable and are expressed as percentages or numbers.
Fisher exact test have been used for carrying out the statistically significant value. i.e. P-value. P-value <0.05 considered to be statistically significant difference.
NS represents non-significant difference between the groups. 
Discussion
The management of renal transplant recipients starts from their peritransplant period. The peritransplant counseling is cardinal for making these patients to understand the effect of pregnancy on grafted kidney and advice regarding best time to conceive. According to American Society of Transplantation Consensus Opinion, as long as graft function is good, patient can conceive. Graft function is considered to be optimum when serum creatinine <1.5 mg/dl, with <500 mg/24 h protein excretion. 3 However, when renal transplant-pregnancy interval is more than 5 years, it may cause persistent impairment of renal function, due to poor tolerance of grafted kidney to the changes of pregnancy 4 but with proper management and follow up this can be prevented. In our study, patients with transplant-pregnancy interval greater than 2 years had good pregnancy outcome with 5 full term and 1 preterm delivery.
During antenatal period, these patients are at risk of developing hypertension, as a result of either preexisting chronic hypertension or gestational hypertension, which needs to be managed aggressively. 3 In our study, out of 16 patients, 9 patients were chronic hypertensive and 2 patients had gestational hypertension. Out of 9 chronic hypertensive patients, 6 had abortion, 2 were mild hypertensive throughout the pregnancy and 1 patient had preeclampsia superimposed on chronic hypertension. Gestational hypertension and mild chronic hypertension was managed with methyl dopa, which is still preferred for mild hypertension as it is well tolerated and does not cause uteroplacental insufficiency. 5 Other antihypertensive agents like labetolol, nifedipine, and thiazide diuretics can be used depending on severity of hypertension. These patients can develop superimposed preeclampsia which causes frightful maternal and fetal complications, like renal failure, liver failure, HELLP syndrome (hemolysis, elevated liver enzymes, and thrombocytopenia), eclampsia, stroke and even maternal mortality. In fetus, it can result in small for gestational age, preterm delivery, hypoxic injury, and fetal loss. 6 It is difficult to diagnose preeclampsia early in renal transplant recipients as they already have proteinuria and blood pressure commonly shoots late in pregnancy. 7 There are chances of graft rejection during pregnancy, but it is difficult to diagnose with fluctuations in serum creatinine. Whenever altered allograft function is detected on graft Doppler, it is important to rule out acute rejection due to preeclampsia and pyelonephritis. If rejection is suspected, kidney biopsy can be taken under ultrasound guidance. 8 There is limited data supporting use of agents like Muromonab-CD3 or anti-thymocyte globulin for treatment of rejection. However, it can be managed alone with corticosteroids. 8 In our study too, one patient had acute graft rejection 2 months after abortion which was managed with plasmapheresis (twice) and corticosteroids. American Society of Transplantation Consensus Conference recommends that in order to prevent graft rejection, dose of immunosuppressant agents should be maintained at pre-pregnancy levels throughout pregnancy. Hence, serum level of these drugs need to monitored during antenatal period. 3, 9 In our study too the levels of immunosuppressant agents were monitored.
Other antenatal complications like gestational diabetes, anemia, and infections such as urinary tract infections can occur. 10, 11 These patients are prone to develop infections like toxoplasmosis and infection with herpes simplex virus, HIV, varicella zoster, hepatitis B or C virus. 12 Prenatal screening should be done to detect these infections and they should be vaccinated with live vaccines like rubella before transplant. In most of the cases, cesarean section is favored mode of delivery but normal vaginal delivery can be conducted uneventfully.
Apart from above mentioned risks, renal transplant recipients are also at high risk for PROM, leading to the increased chances for preterm delivery and low birth weight babies. 8 Hence, it is recommended to give steroids late in pregnancy (between 28 and 34 weeks) to promote lung maturity. 6 The incidence of intrauterine growth restriction is 30-50%, because of adverse effects of preexisting hypertension and kidney disease. 8, 13 Therefore, along with mother, it is important to closely monitor fetal growth to diagnose fetal growth restriction at earliest. 8 Throughout pregnancy, fetuses of these patients are being exposed to immunosuppressive drugs which can affect organogenesis and fetal growth. The current recommendations are to avoid mycophenolate mofetil and rapamycin for 6 weeks before pregnancy because they are associated with severe structural deformities. 3, 14 There is a long list of immunosuppressive agents but most commonly used during pregnancy are steroids, tacrolimus, azathioprine and cyclosporine. Tacrolimus and cyclosporine are included in FDA category C, while steroids are included in FDA category B and azathioprine in FDA category D. 14 Short acting glucocorticoids like prednisolone is preferred in renal transplant recipient. Its use in pregnancy is associated with increased risk for PROM and can aggravate hypertension. Cases of cleft palate and mental retardation have been reported with its use. 15 Serious maternal infection can occur with increased doses of prednisone (greater than 20 mg/day). Azathioprine also carries risk of congenital malformations that ranges from 4 to 9%; however, these malformations have had no specific pattern. It can cause low birth weights babies, preterm deliveries, jaundice and respiratory distress syndrome. Azathioprine also has been associated with a dose-related myelosuppression in the fetus. 16 On the other hand, use of cyclosporine and tacrolimus during pregnancy are associated with low birth weights and higher incidence of maternal diabetes, hypertension and renal allograft dysfunction. Cyclosporine also increases production of thromboxane and endothelin, which are involved in pathogenesis of preeclampsia. Due to this reason dose of cyclosporine should be limited to 2-4 mg/kg per day. 17 
Conclusion
The number of females undergoing renal transplant are increasing with time and also longevity of life. Proper counseling regarding optimal time to conceive and effect of pregnancy on their grafted kidney is very important and should be individualized according to their graft functioning. Transplant-pregnancy interval and pre-pregnancy serum creatinine are important factors in predicting pregnancy outcomes. These patients fall in high risk group, but can have good pregnancy outcome with regular antenatal and postnatal follow up.
